Skip to main content
main-content

Prostate cancer

Prostate cancer

12-05-2021 | Oncology | Highlight | Article

COVID-19 leaves large cancer screening deficit in USA

Breast, prostate, and colorectal cancer screening rates declined sharply during the initial months of the COVID-19 pandemic in the USA, and while they subsequently recovered, a large deficit remains, study findings indicate.

06-05-2021 | Oncology | News | Article

TITAN final analysis confirms apalutamide benefit in mCSPC

Men with metastatic castration-sensitive prostate cancer continue to derive a survival benefit from the addition of apalutamide to androgen deprivation therapy, suggest long-term data from the TITAN trial.

28-04-2021 | Oncology | News | Article

AHA issues statement on managing hormonal therapy-related CVD risks

The American Heart Association has released a consensus statement on the management of cardiovascular disease in patients receiving hormonal therapies for breast or prostate cancer.

28-04-2021 | Oncology | News | Article

Cardiovascular AEs of prostate cancer hormone therapies reported

An analysis of the FDA Adverse Event Reporting System has provided detailed insight into cardiovascular adverse events associated with different classes of androgen deprivation therapies.

22-04-2021 | Oncology | News | Article

Limited evidence to link antihypertensive use to cancer

An extensive meta-analysis of individual participant data has not found consistent evidence to indicate that antihypertensive use is associated with an increased risk for cancer.

13-04-2021 | Oncology | News | Article

Healthy lifestyle may attenuate lethal prostate cancer risk

Men with a high genetic risk for developing prostate cancer may be able to offset the risk for lethal disease by maintaining a healthy lifestyle, findings indicate.

12-04-2021 | Oncology | News | Article

mCRPC with immunogenic signature may respond to nivolumab plus ipilimumab

Combination therapy with nivolumab and ipilimumab has shown antitumor activity in a phase 2 study of men with metastatic castration-resistant prostate cancer and a positive immunogenic signature.

31-03-2021 | Oncology | News | Article

Worse cancer outcomes in areas of deprivation transcend access to quality care

Researchers have identified an association between socioeconomic deprivation and poor survival in people with cancer participating in clinical trials.

23-03-2021 | Oncology | News | Article

PROSINT: Single dose of radiation ‘feasible’ for organ-confined prostate cancer

One ultra-high dose of radiation may offer similar benefits and risks to those of an extreme hypofractionated stereotactic body radiotherapy regimen for men with organ-confined prostate cancer, indicate the results of a phase 2 proof-of-concept trial.

16-03-2021 | Oncology | News | Article

Bone metastases features may predict radiotherapy benefit in prostate cancer

The number and location of bone metastases, as determined by conventional imaging, are associated with the survival benefit of prostate radiotherapy in men with newly diagnosed metastatic prostate cancer, STAMPEDE trial data show.

22-02-2021 | Oncology | News | Article

Novel risk score may enable treatment de-escalation in some prostate cancer patients

The clinical cell-cycle risk score is able to accurately predict metastasis risk in men undergoing dose-escalated radiation therapy, with or without androgen deprivation therapy, for intermediate- to high-risk localized prostate cancer, research suggests.

19-02-2021 | Oncology | News | Article

Dose intensification adds no benefit to post-prostatectomy salvage radiotherapy

Dose intensification does not improve the outcomes of salvage radiotherapy after radical prostatectomy, the SAKK 09/10 investigators have reported at the 2021 Genitourinary Cancers Symposium.

16-02-2021 | Oncology | News | Article

LuPSMA ‘promising alternative’ to cabazitaxel in mCRPC

The radiolabeled small molecule lutetium-177-prostate-specific membrane antigen-617 offers higher activity and better patient-reported outcomes than cabazitaxel in metastatic castration-resistant prostate cancer, research shows.

16-02-2021 | Oncology | News | Article

Immunotherapy–docetaxel combinations show promise in mCRPC

Combining a PD-1 inhibitor with docetaxel could benefit chemotherapy-naïve men with metastatic castration-resistant prostate cancer, suggest results from two early-phase trials.

15-02-2021 | Oncology | News | Article

Radiotherapy activity changed significantly during first COVID-19 peak

The total number of radiotherapy courses delivered in England fell significantly during the first peak of the COVID-19 pandemic but this was accompanied by a rapid increase in the use of hypofractionated regimens, study data show.

14-02-2021 | Oncology | News | Article

Biomarkers of apalutamide response identified in nonmetastatic CRPC

Further analysis of patients with nonmetastatic castration-resistant prostate cancer from the SPARTAN trial has identified molecular biomarkers associated with long-term responses to apalutamide.

12-02-2021 | Oncology | News | Article

COVID-19: More evidence against protective effect of ADT

A large study has failed to find an association between receipt of androgen deprivation therapy and a reduced risk for SARS-CoV-2 infection.

12-02-2021 | Oncology | News | Article

Combining apalutamide, abiraterone boosts mCRPC radiographic PFS

Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer derive a significant radiographic progression-free survival benefit from the addition of apalutamide to abiraterone acetate, suggest phase 3 trial data.

12-02-2021 | Oncology | News | Article

Fall in PSA screening linked to rise in metastatic prostate cancer diagnoses

The decrease in PSA screening in recent years may have come at the cost of increased levels of later-stage disease at prostate cancer diagnosis, suggests research presented at the 2021 Genitourinary Cancers Symposium.

09-02-2021 | Oncology | News | Article

Network meta-analysis identifies best ADT add-ons for mCSPC

Abiraterone acetate or apalutamide given in combination with androgen deprivation therapy offer the best survival outcomes for patients with metastatic castration-sensitive prostate cancer, a network meta-analysis shows.

Image Credits